C. Difficile

The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been busy this year in Washington DC with an FDA event and their Summit and Advocacy Day with lawmakers.

Inhibiting production of para-cresol could be effective against Clostridioides difficile infection by reducing the pathogen’s ability to compete with other bacteria in the gut microbiome, a new study found.

In a comprehensive economic evaluation, researchers assessed the cost-effectiveness of monoclonal antibodies as a preventive strategy for COVID-19.

Stay informed about the long-term effects of COVID-19, prevention strategies for recurrent C diff, and the emerging threat of drug-resistant Candida auris.

FMT is a promising intervention for immunocompetent patients with recurrent C difficile infection. However, the safety of FMT remains inconclusive due to limited data on serious adverse events and mortality.

From FDA recalls to a new COVID-19 variant, infectious disease news did not slow down in June. Catch up with Contagion's monthly recap of our most-clicked articles.

Competition among species has therapeutic implications, the authors found.

In phase 3 studies, the company’s investigational therapy, aztreonam-avibactam (ATM-AVI), had favorable results over other treatments used for complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).

As the first line of acute care, emergency departments are key stewards of antibiotics.

A study of hospitalized patients with diarrhea found that collecting stool samples and testing all of them identified almost 30% more cases of C. diff than the standard of care.

Rates of hospital-onset multidrug-resistant P aeruginosa infections have increased significantly in recent years.

Due to worsening headaches and unrevealing cross-sectional imaging and ascites fluid analyses, this patient's differential evolved toward a central nervous system source.

Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.

Joseph Reilly, BS, PharmD, BCGP, reviews the positive economic impact of use of live-jslm for treatment of CDI in a hospital setting.

Experts comment on the measures that need to be taken to prevent or control the spread of CDI in the healthcare setting.

The update includes several different infections, and offers brief descriptions of significant clinical trials, resistance mechanisms, and antimicrobial susceptibility testing methods for each of the pathogens.

The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been working to help people affected by the healthcare associated infection and getting involved with public advocacy including their support of the prospective antibiotic-related law, the Pasteur Act.

Unnecessary antibiotics for viral infections and incorrect prescriptions for bacterial infections have significant consequences, including increased adverse effects and healthcare expenditures.

As the official COVID-19 emergency is declared over, our Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on the public health response, the scientific successes, and the shortcomings that were experienced.

The federal lawsuit filed in court looks to stop the government’s plan to negotiate therapy prices.

With the CDC’s recent warning about it, this fungal infection is becoming more prevalent and is often multidrug resistant. Here are some infection prevention strategies to protect against its spread in health care facilities, where it is most common.

The federal agency gave Merck the nod to use the company's antiviral as prophylaxis for Cytomegalovirus Disease (CMV), postoperatively.

Findings indicate that while the severity of health impairment decreases over time, 18% of unvaccinated participants still experience symptoms up to 2 years after infection.

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

Candace Cotto, RN, and Andrew Skinner, MD, discuss barriers to use of FMTs in managing CDI, highlighting clinician and patient education.

Experts comment on insurance coverage as a factor for the broader use of FMTs for the management of CDI.

The Mexican Ministry of Health sent the CDC a list of over 200 US patients who may have been exposed to the fungal infection.

There has been a low uptake of bivalent mRNA booster vaccines in older adults, despite a high efficacy of preventing severe and fatal COVID-19.

Candace Cotto, RN, reviews the process of incorporating fecal microbiota, live-jslm treatment into clinical practice, what patients can expect, and the room sanitation process after the procedure.

Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.